Mutations in the activation loop of the tyrosine kinase domain (TKD1) of FLT3 are present in up to 30% of patients with acute myeloid leukemia (AML), and FLT3 has been utilized as a potential target for kinase inhibitor therapy [19,20]. This evidence concerns the gene FLT3 and acute myeloid leukemia.